Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 34 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Hyperpolarized 129Xe Clear all
Completed Phase 4 Interventional

Hyperpolarized Imaging for New Treatments

NCT04259970
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 18 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
3
States / cities
Cincinnati, Ohio • Charlottesville, Virginia • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Hyperpolarized 129Xe MRI for Imaging Pulmonary Function

NCT01280994
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Hyperpolarized 129Xenon Gas
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Hyperpolarized Xenon-129 Magnetic Resonance Imaging and Spectroscopy of Brown Fat: Healthy Adult Volunteer Pilot Study

NCT02220426
View directory record Official record
Conditions
Obesity
Interventions
Xenon
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 18, 2026, 4:15 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

129Xe MRI in Pediatric Population With BPD

NCT04035629
View directory record Official record
Conditions
Bronchopulmonary Dysplasia
Interventions
MagniXene, hyperpolarized 129Xe MRI
Combination Product
Lead sponsor
Xemed LLC
Industry
Eligibility
Up to 1 Year
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2031
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Optimizing and Standardizing 129Xe Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

NCT04855305
View directory record Official record
Conditions
Interstitial Lung Diseases
Interventions
Hyperpolarized 129Xe
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

NCT04624490
View directory record Official record
Conditions
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
Mario Castro, MD, MPH
Other
Eligibility
3 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Effects of Bevespi on Ventilation and Gas Exchange Abnormalities in COPD Assessed by 129Xe MRI

NCT03324607
View directory record Official record
Conditions
COPD
Interventions
hyperpolarized 129Xe gas MRI, Bevespi Aerosphere
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
40 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Oct 18, 2026, 4:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigating Radiation-response and Toxicity

NCT06909201
View directory record Official record
Conditions
Lung Cancer
Interventions
HP 129Xe MRI
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 1 Interventional

Hyperpolarized 129Xe MRI of Survivors of COVID-19

NCT04659707
View directory record Official record
Conditions
Covid19
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional

129 Xenon Imaging in Patients Treated With Sotatercept

NCT06351345
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

129Xe MRI Cardiopulmonary

NCT06038630
View directory record Official record
Conditions
Interstitial Lung Disease, Chronic Thromboembolic Pulmonary Hypertension, Acute Pulmonary Embolism, Anemia, Polycythemia, Dyspnea
Interventions
Hyperpolarized Xe129, Oxygen Administration
Drug · Other
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Active, not recruiting Phase 4 Interventional

BEGIN Novel ImagiNG Biomarkers

NCT05517655
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
129Xe
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 8 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Assessing Response to Inhaled Prostacyclin With Hyperpolarized Xe MRI

NCT03367312
View directory record Official record
Conditions
Pulmonary Vascular Disease
Interventions
Hyperpolarized 129Xenon gas
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 18, 2026, 4:15 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Non-contrast Lung Perfusion Mapping Applied for New Insights in Cystic Fibrosis

NCT04467957
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Initiation of CFTR Modulator, Hyperpolarized Xenon 129
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Use of Hyperpolarized 129Xe MR Lung Imaging in Adults for Calibration

NCT02316379
View directory record Official record
Conditions
Respiratory Disorders
Interventions
Hyperpolarized 129 Xenon, MRI
Drug · Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2032
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Comparison of 129Xe MRI With 19F MRI in CF Lung Disease

NCT03482960
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Hyperpolarized Xenon gas, PFP
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Oct 18, 2026, 4:15 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Gas Exchange MRI to Visualize Regional Therapy Response in Interstitial Lung Disease

NCT06012500
View directory record Official record
Conditions
ILD
Interventions
Xenon-129
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 3 Interventional

Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Transplant

NCT03418090
View directory record Official record
Conditions
Pulmonary Surgical Procedures
Interventions
129Xe MRI, 133XE scintigraphy
Drug
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Durham, North Carolina • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Oct 18, 2026, 4:15 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Functional Applications of Hyperpolarized 129Xe MRI

NCT01697332
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Hyperpolarized 129Xe gas
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
20 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Results available

Hyperpolarized Xenon MRI for Assessment of Pulmonary Function in Lung Resection

NCT03417687
View directory record Official record
Conditions
Pulmonary Surgical Procedures
Interventions
129Xe MRI, 133 Xe scintigraphy
Drug
Lead sponsor
Polarean, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
Durham, North Carolina • Cincinnati, Ohio • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 18, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional

Xenon MRI Pulm Hypertension

NCT04991454
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Recruiting Phase 2 Interventional

129 Xenon MRI as a Biomarker for Diagnosis and Response to Therapy in Pulmonary Arterial Hypertension (PAH)

NCT06104228
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension Associated With Connective Tissue Disease (Disorder), Connective Tissue Diseases
Interventions
129Xe Hyperpolarized
Drug
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 18, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis

NCT02478268
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
Hyperpolarized 129-Xenon gas, MRI
Drug · Device
Lead sponsor
Bastiaan Driehuys
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Durham, North Carolina • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Oct 18, 2026, 4:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Regional Phenotyping of CF and Non-CF Bronchiectasis

NCT04793867
View directory record Official record
Conditions
Cystic Fibrosis, Non-CF Bronchiectasis
Interventions
Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 18, 2026, 4:15 AM EDT